MY ACCOUNT | NEWSLETTER |

Global pet diabetes care market to reach $2.8B by 2027


The global pet diabetes care market size reached $1.71 billion in 2021. Looking forward, analysts expect the market to reach $2.76 billion by 2027, exhibiting a CAGR of 8.31%.

Pet diabetes care refers to continuous monitoring of blood sugar levels in animals caused by insulin production. It is a common and prominent metabolic disease that frequently affects pets, such as dogs, cats, and livestock.

It includes insulin therapy and oral medications that stabilize blood sugar levels, help regulate the level of glucose in the bloodstream and control the delivery of glucose to the tissues of the body.

According to a news release from Research and Markets, the increasing number of pet parents who are aware of the overall health and well-being of pets and routinely seek veterinary services are creating a positive outlook for the market, according to Research and Markets. Additionally, the widespread adoption of insulin treatment for diabetic dogs and cats that reduces blood glucose levels by increasing peripheral consumption of glucose and suppressing the production of hepatic glucose is favoring the market growth.

Moreover, the introduction of smart wearable devices integrated with artificial intelligence (AI), machine learning and the Internet of Things for remotely tracking pets' health is proving an impetus to the market growth. In line with this, the launch of highly targeted and specific drugs for diabetes in pets with minimal side effects is positively influencing the market growth.

Learn more about the new report from Research and Markets on the company’s website. 

Like1
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Zoetis is Redefining the Feline Veterinary Experience with the Commercial Launch of Bonqat® (pregabalin oral solution) in the U.S.

Like0
Dislike0

Spatio-temporal patterns of tick-borne disease diagnoses in Indiana, USA (2009–2018)

Like0
Dislike0

Abdominal ultrasonographic findings of cats with feline infectious peritonitis: an update

Like0
Dislike0

Pseudohyperkalemia in horses with rhabdomyolysis reported by an enzymatic chemistry analyzer

Like0
Dislike0

Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2024 - All Rights Reserved
ISSN 2768-198X

Top